As type I IFNs activate NK cells on one hand and limit their efficacy on tumor cells on the other hand, by increasing the expression of PD-1 on NK cells and PD-L1 on tumor cells, the combined application of these two agents could increase anti-tumor efficacy. Here, CD274 is linked to neoplasm.